Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring.

Liu T, Kotha RR, Jones JW, Polli JE, Kane MA.

J Pharm Biomed Anal. 2019 Aug 17;176:112816. doi: 10.1016/j.jpba.2019.112816. [Epub ahead of print]

PMID:
31465890
2.

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.

Rajawat GS, Belubbi T, Nagarsenker MS, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Parr A, Polli JE, Mehta M, Shah VP, Tajiri T, Dressman J.

J Pharm Sci. 2019 Jun 8. pii: S0022-3549(19)30366-1. doi: 10.1016/j.xphs.2019.05.033. [Epub ahead of print]

PMID:
31181225
3.

Pig-a gene mutation database.

Shemansky JM, McDaniel LP, Klimas C, Dertinger SD, Dobrovolsky VN, Kimoto T, Horibata K, Polli JE, Heflich RH.

Environ Mol Mutagen. 2019 May 15. doi: 10.1002/em.22298. [Epub ahead of print]

PMID:
31090953
4.

Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.

Neu HM, Alexishin SA, Brandis JEP, Williams AMC, Li W, Sun D, Zheng N, Jiang W, Zimrin A, Fink JC, Polli JE, Kane MA, Michel SLJ.

Mol Pharm. 2019 Mar 4;16(3):1272-1281. doi: 10.1021/acs.molpharmaceut.8b01215. Epub 2019 Feb 14.

PMID:
30676753
5.

Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy.

Das S, Pu X, Jiang X, Jiang W, Tung R, Ting TY, Polli JE.

Epilepsy Behav. 2019 Jan;90:197-203. doi: 10.1016/j.yebeh.2018.11.039. Epub 2018 Dec 20.

PMID:
30579779
6.

Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).

Zhu P, Ye Z, Guo D, Xiong Z, Huang S, Guo J, Zhang W, Polli JE, Zhou H, Li Q, Shu Y.

Pharm Res. 2018 Oct 25;35(12):243. doi: 10.1007/s11095-018-2526-y.

7.

Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice.

Metry M, Felton J, Cheng K, Xu S, Ai Y, Xue F, Raufman JP, Polli JE.

Mol Pharm. 2018 Nov 5;15(11):4827-4834. doi: 10.1021/acs.molpharmaceut.8b00454. Epub 2018 Oct 3.

PMID:
30247920
8.

Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.

Guo D, Yang H, Li Q, Bae HJ, Obianom O, Zeng S, Su T, Polli JE, Shu Y.

Pharm Res. 2018 Sep 6;35(11):204. doi: 10.1007/s11095-018-2486-2.

9.

Authorized Generic Drugs: an Overview.

Gulsen Oner Z, Polli JE.

AAPS PharmSciTech. 2018 Aug;19(6):2450-2458. doi: 10.1208/s12249-018-1073-5. Epub 2018 Jun 25. Review.

PMID:
29943278
10.

Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice.

Cheng K, Metry M, Felton J, Shang AC, Drachenberg CB, Xu S, Zhan M, Schumacher J, Guo GL, Polli JE, Raufman JP.

Oncotarget. 2018 May 22;9(39):25572-25585. doi: 10.18632/oncotarget.25385. eCollection 2018 May 22.

11.

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride.

Plöger GF, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Parr A, Polli JE, Shah VP, Tajiri T, Dressman JB.

J Pharm Sci. 2018 Jul;107(7):1761-1772. doi: 10.1016/j.xphs.2018.03.009. Epub 2018 Mar 20. Review.

PMID:
29571740
12.

Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1).

Li Q, Ye Z, Zhu P, Guo D, Yang H, Huang J, Zhang W, Polli JE, Shu Y.

Pharm Res. 2018 Jan 4;35(1):14. doi: 10.1007/s11095-017-2290-4.

PMID:
29302757
13.

Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.

Oner ZG, Michel SLJ, Polli JE.

Ann N Y Acad Sci. 2017 Nov;1407(1):26-38. doi: 10.1111/nyas.13505. Epub 2017 Nov 1. Review.

PMID:
29090833
14.

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid.

Hofsäss MA, Souza J, Silva-Barcellos NM, Bellavinha KR, Abrahamsson B, Cristofoletti R, Groot DW, Parr A, Langguth P, Polli JE, Shah VP, Tajiri T, Mehta MU, Dressman JB.

J Pharm Sci. 2017 Dec;106(12):3421-3430. doi: 10.1016/j.xphs.2017.08.007. Epub 2017 Aug 24.

PMID:
28842299
15.

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.

Thambavita D, Galappatthy P, Mannapperuma U, Jayakody L, Cristofoletti R, Abrahamsson B, Groot DW, Langguth P, Mehta M, Parr A, Polli JE, Shah VP, Dressman J.

J Pharm Sci. 2017 Oct;106(10):2930-2945. doi: 10.1016/j.xphs.2017.04.068. Epub 2017 May 5. Review.

PMID:
28483422
16.

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril.

Verbeeck RK, Kanfer I, Löbenberg R, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Polli JE, Parr A, Shah VP, Mehta M, Dressman JB.

J Pharm Sci. 2017 Aug;106(8):1933-1943. doi: 10.1016/j.xphs.2017.04.019. Epub 2017 Apr 21. Review.

PMID:
28435140
17.

Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Martinez MN, Mistry B, Lukacova V, Lentz KA, Polli JE, Hoag SW, Dowling T, Kona R, Fahmy RM.

AAPS J. 2017 May;19(3):712-726. doi: 10.1208/s12248-017-0055-y. Epub 2017 Mar 6.

PMID:
28265981
18.

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport.

Felton J, Cheng K, Said A, Shang AC, Xu S, Vivian D, Metry M, Polli JE, Raufman JP.

J Vis Exp. 2016 Nov 27;(117). doi: 10.3791/54597.

19.

Multidrug and toxin extrusion proteins mediate cellular transport of cadmium.

Yang H, Guo D, Obianom ON, Su T, Polli JE, Shu Y.

Toxicol Appl Pharmacol. 2017 Jan 1;314:55-62. doi: 10.1016/j.taap.2016.11.007. Epub 2016 Nov 18.

20.

Erratum to: Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the Absorption of a Low Solubility Compound: Ciprofloxacin.

Martinez M, Mistry B, Lukacova V, Polli JE, Hoag SW, Dowling T, Kona R, Fahmy R.

AAPS J. 2016 Nov;18(6):1584. No abstract available.

PMID:
27215600
21.

Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid.

Dickinson PA, Kesisoglou F, Flanagan T, Martinez MN, Mistry HB, Crison JR, Polli JE, Cruañes MT, Serajuddin ATM, Müllertz A, Cook JA, Selen A.

J Pharm Sci. 2016 Nov;105(11):3243-3255. doi: 10.1016/j.xphs.2016.07.024. Epub 2016 Sep 19. Review.

PMID:
27659159
22.

Release of levetiracetam from extended-release tablets that appear intact in patient stool.

Vaithianathan S, Ting TY, Jiang W, Polli JE.

Seizure. 2016 Aug;40:7-9. doi: 10.1016/j.seizure.2016.05.011. Epub 2016 May 25. No abstract available.

23.

Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs.

Raman S, Polli JE.

Int J Pharm. 2016 Jun 15;506(1-2):110-5. doi: 10.1016/j.ijpharm.2016.04.013. Epub 2016 Apr 8.

PMID:
27067239
24.

Reply to "On the Effect of Common Excipients on the Oral Absorption of Class 3 Drugs".

Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE.

J Pharm Sci. 2016 Apr;105(4):1355-7. doi: 10.1016/j.xphs.2016.02.028.

PMID:
27019956
25.

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin.

Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Polli JE, Shah VP, Dressman JB.

J Pharm Sci. 2016 Apr;105(4):1362-9. doi: 10.1016/j.xphs.2016.01.017. Epub 2016 Mar 5.

PMID:
26952879
26.

Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.

Li Q, Yang H, Guo D, Zhang T, Polli JE, Zhou H, Shu Y.

Drug Metab Dispos. 2016 Apr;44(4):489-94. doi: 10.1124/dmd.115.067223. Epub 2016 Jan 29.

27.

Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir.

Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE.

J Pharm Sci. 2016 Feb;105(2):996-1005. doi: 10.1002/jps.24643. Epub 2016 Jan 12.

PMID:
26375604
28.

Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.

Raufman JP, Dawson PA, Rao A, Drachenberg CB, Heath J, Shang AC, Hu S, Zhan M, Polli JE, Cheng K.

Carcinogenesis. 2015 Oct;36(10):1193-200. doi: 10.1093/carcin/bgv107. Epub 2015 Jul 25.

29.

Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.

Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE.

Epilepsia. 2015 Sep;56(9):1415-24. doi: 10.1111/epi.13095. Epub 2015 Jul 23.

30.

Gordon L. Amidon: Very Sustained Drug Absorption.

Donovan MD, Polli JE, Langguth P, Tamai I, Vig B, Yu LX.

J Pharm Sci. 2015 Sep;104(9):2650-63. doi: 10.1002/jps.24523. Epub 2015 Jun 5. No abstract available.

PMID:
26053319
31.

Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets.

Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE.

Mol Pharm. 2015 Jul 6;12(7):2436-43. doi: 10.1021/acs.molpharmaceut.5b00154. Epub 2015 Jun 2.

PMID:
26001027
32.

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam.

Petruševska M, Berglez S, Krisch I, Legen I, Megušar K, Peternel L, Abrahamsson B, Cristofoletti R, Groot DW, Kopp S, Langguth P, Mehta M, Polli JE, Shah VP, Dressman J.

J Pharm Sci. 2015 Sep;104(9):2676-87. doi: 10.1002/jps.24350. Epub 2015 Feb 6. Review.

PMID:
25663270
33.

Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver.

Dong Z, Li Q, Guo D, Shu Y, Polli JE.

J Pharm Sci. 2015 Sep;104(9):2864-76. doi: 10.1002/jps.24375. Epub 2015 Feb 2.

34.

A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide.

Dong Z, Ekins S, Polli JE.

Int J Pharm. 2015 Jan 15;478(1):88-95. doi: 10.1016/j.ijpharm.2014.11.022. Epub 2014 Nov 13.

35.

Quality-by-design III: application of near-infrared spectroscopy to monitor roller compaction in-process and product quality attributes of immediate release tablets.

Kona R, Fahmy RM, Claycamp G, Polli JE, Martinez M, Hoag SW.

AAPS PharmSciTech. 2015 Feb;16(1):202-16. doi: 10.1208/s12249-014-0180-1. Epub 2014 Oct 16.

36.

The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.

Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin ATM, Cook JA, Dressman JB.

J Pharm Sci. 2014 Nov;103(11):3377-3397. doi: 10.1002/jps.24162. Epub 2014 Sep 24. Review.

PMID:
25256402
37.

Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition.

Dong Z, Ekins S, Polli JE.

Eur J Pharm Sci. 2015 Jan 23;66:1-9. doi: 10.1016/j.ejps.2014.09.005. Epub 2014 Sep 16.

38.

Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver.

Vivian D, Polli JE.

Int J Pharm. 2014 Nov 20;475(1-2):597-604. doi: 10.1016/j.ijpharm.2014.09.014. Epub 2014 Sep 16.

39.

Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging.

Vivian D, Cheng K, Khurana S, Xu S, Dawson PA, Raufman JP, Polli JE.

J Pharm Sci. 2014 Nov;103(11):3782-3792. doi: 10.1002/jps.24131. Epub 2014 Sep 5.

40.

Mechanistic interpretation of conventional Michaelis-Menten parameters in a transporter system.

Vivian D, Polli JE.

Eur J Pharm Sci. 2014 Nov 20;64:44-52. doi: 10.1016/j.ejps.2014.08.007. Epub 2014 Aug 27.

41.

Quantification of lamotrigine in patient plasma using a fast liquid chromatography-tandem mass spectrometry method with backflush technology.

Wong JM, Jones JW, Jiang W, Polli JE, Kane MA.

Ther Drug Monit. 2015 Apr;37(2):188-97. doi: 10.1097/FTD.0000000000000123.

PMID:
25162213
42.

Biowaiver monographs for immediate-release solid oral dosage forms: codeine phosphate.

Dahan A, Wolk O, Zur M, Amidon GL, Abrahamsson B, Cristofoletti R, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Dressman JB.

J Pharm Sci. 2014 Jun;103(6):1592-600. doi: 10.1002/jps.23977. Epub 2014 May 1.

43.

In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport.

Vivian D, Cheng K, Khurana S, Xu S, Kriel EH, Dawson PA, Raufman JP, Polli JE.

Mol Pharm. 2014 May 5;11(5):1575-82. doi: 10.1021/mp400740c. Epub 2014 Apr 18.

44.

Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.

Gandhi SV, Rodriguez W, Khan M, Polli JE.

AAPS PharmSciTech. 2014 Jun;15(3):601-11. doi: 10.1208/s12249-014-0084-0. Epub 2014 Feb 21.

45.

The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity.

Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H.

Drug Metab Dispos. 2014 Mar;42(3):318-22. doi: 10.1124/dmd.113.054189. Epub 2013 Dec 12.

46.

Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids.

González PM, Lagos CF, Ward WC, Polli JE.

Mol Pharm. 2014 Feb 3;11(2):588-98. doi: 10.1021/mp400575t. Epub 2013 Dec 26.

47.

Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.

Shohin IE, Kulinich JI, Ramenskaya GV, Abrahamsson B, Kopp S, Langguth P, Polli JE, Shah VP, Groot DW, Barends DM, Dressman JB.

J Pharm Sci. 2014 Feb;103(2):367-77. doi: 10.1002/jps.23799. Epub 2013 Dec 2.

PMID:
24301077
48.

Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).

Li Q, Guo D, Dong Z, Zhang W, Zhang L, Huang SM, Polli JE, Shu Y.

Toxicol Appl Pharmacol. 2013 Nov 15;273(1):100-9. doi: 10.1016/j.taap.2013.08.024. Epub 2013 Aug 31.

49.

Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine).

Soares KC, Rediguieri CF, Souza J, Serra CH, Abrahamsson B, Groot DW, Kopp S, Langguth P, Polli JE, Shah VP, Dressman J.

J Pharm Sci. 2013 Aug;102(8):2409-23. doi: 10.1002/jps.23624. Epub 2013 Jun 10. Review.

PMID:
23754446
50.

Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1.

Li Q, Yang H, Peng X, Guo D, Dong Z, Polli JE, Shu Y.

Mol Pharm. 2013 Jul 1;10(7):2578-87. doi: 10.1021/mp400013t. Epub 2013 Jun 3.

Supplemental Content

Loading ...
Support Center